Ombitasvir

Ombitasvir
Clinical data
Trade names	Viekira Pak (with ombitasvir, paritaprevir, ritonavir and dasabuvir), Technivie (with ombitasvir, paritaprevir, and ritonavir)
Other names	ABT-267
Routes of; administration	Oral
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	not determined
Protein binding	~99.9%
Metabolism	amide hydrolysis followed by oxidation
Onset of action	~4 to 5 hours
Elimination half-life	21 to 25 hours
Excretion	mostly with feces (90.2%)
Identifiers
	IUPAC name Dimethyl ({(2S,5S)-1-[4-(2-methyl-2-propanyl)phenyl]-2,5-pyrrolidinediyl}bis{4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediyl[(2S)-3-methyl-1-oxo-1,2-butanediyl]})biscarbamate;
CAS Number	1258226-87-7;
PubChem CID	54767916;
ChemSpider	31136214;
ChEBI	CHEBI:85183 ;
CompTox Dashboard (EPA)	DTXSID201027920 ;
Chemical and physical data
Formula	C50H67N7O8
Molar mass	894.11 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc2ccc(cc2)[C@@H]3CC[C@H](N3c4ccc(cc4)C(C)(C)C)c5ccc(cc5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC;
	InChI InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1; Key:PIDFDZJZLOTZTM-KHVQSSSXSA-N;

Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1^[1]^[2], and with paritaprevir and ritonavir in the product Technivie for the treatment of HCV genotype 4^[3]^[4].

Ombitasvir acts by inhibiting the HCV protein NS5A.^[5]

References

^ "VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), for Oral Use. Full Prescribing Information" (PDF). AbbVie Inc., North Chicago, IL 60064. Retrieved 30 July 2015.
^ "FDA approves Viekira Pak to treat hepatitis C". Food and Drug Administration. December 19, 2014.
^ "TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) Tablets, for Oral Use. Full Prescribing Information" (PDF). AbbVie Inc., North Chicago, IL 60064. Retrieved 28 July 2015.
^ "FDA approves Technivie for treatment of chronic hepatitis C genotype 4". Food and Drug Administration. July 24, 2015.
^ Jordan J. Feld, Kris V. Kowdley, Eoin Coakley, Samuel Sigal, David R. Nelson, Darrell Crawford, Ola Weiland, Humberto Aguilar, Junyuan Xiong, Tami Pilot-Matias, Barbara DaSilva-Tillmann, Lois Larsen, Thomas Podsadecki, and Barry Bernstein (2014). "Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin". N Engl J Med. 370: 1594–1603. doi:10.1056/NEJMoa1315722.{{cite journal}}: CS1 maint: multiple names: authors list (link)

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.